Tg Therapeutics (TGTX) EBT (2011 - 2026)

Tg Therapeutics' EBT history runs 16 years deep, the most recent figure standing at $20.4 million for Q1 2026.

• In Q1 2026, EBT rose 272.4% year-over-year to $20.4 million; the TTM figure through Mar 2026 stood at $122.6 million (up 187.77% YoY), while the FY2025 annual figure was $107.7 million, up 307.02% from the prior year.
• EBT for Q1 2026 stood at $20.4 million, down from $45.4 million in the prior quarter.
• The five-year high for EBT was $113.9 million in Q3 2023, with the low at -$75.7 million in Q4 2022.
• The 5-year median for EBT is $4.3 million (2024), against an average of -$4.7 million.
• The sharpest annual moves came in 2024 and 2025: EBT tumbled 96.25% in 2024, then jumped 507.05% in 2025.
• Tg Therapeutics' EBT stood at -$75.7 million in 2022, then soared by 81.46% to -$14.0 million in 2023, then surged by 287.72% to $26.3 million in 2024, then jumped by 72.59% to $45.4 million in 2025, then plunged by 55.19% to $20.4 million in 2026.
• Business Quant data shows TGTX's EBT at $20.4 million in Q1 2026, $45.4 million in Q4 2025, and $25.9 million in Q3 2025.